


PF-610355

Cat. No.:	HY-14296
CAS No.:	862541-45-5
Molecular Formula:	C ₃₄ H ₃₉ N ₃ O ₆ S
Molecular Weight:	617.75
Target:	Adrenergic Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PF-610355 is a long-acting inhaled β_2 -adrenoreceptor agonist, with an EC ₅₀ of 0.26 nM. PF-610355 has the potential for the study of asthma and COPD ^[1] .
In Vivo	PF-610355 is a long-acting (once daily) inhaled β_2 -adrenoreceptor agonist. PF-610355 has low oral bioavailability due to poor absorption through the gut lumen and high first pass metabolism and warranted further progression. PF-610355 has a short half-life (Cl _{int} = 33 (μL/min)/mg) that suggested an unbound intrinsic clearance of >10000 (mL/min)/kg. PF-610355 exhibits an ideal pharmacokinetic profile for an inhaled agent ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Glossop PA, et al. Inhalation by design: novel ultra-long-acting $\beta(2)$ -adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. *J Med Chem.* 2010 Sep 23;53(18):6640-52.
- [2]. Fuso L, et al. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. *Curr Med Chem.* 2013;20(12):1477-95.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA